US · ESLA
Estrella Immunopharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- EmeryVille, CA 94608
- Website
- estrellabio.com
Price · as of 2024-12-31
$1.63
Market cap 51.28M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | $0.99 |
AI valuation
Our deep-learning model estimates Estrella Immunopharma, Inc.'s (ESLA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.63
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ESLA | Estrella Immunopharma, In… | $1.63 | 51.28M | — | — | — | — | -4.10 | 252.14 | — | -3.99 | — | 252.14 | 0.00% | — | — | — | — | — | 0.00 | — | 0.55 | 0.31 | 0.10 | — | — | — | -21.08% | -2.55 | — | 0.00% | 0.00% | 1.57% | -3.99 | -4.62 | — | -13.22 |
| ANEB | Anebulo Pharmaceuticals, … | $0.36 | 14.68M | — | — | — | — | -9.49 | 6.90 | — | -8.50 | — | 6.90 | 0.00% | — | — | -109.69% | -2464.82% | -104.63% | 0.00 | -24.14 | 53.36 | 52.20 | 1.44 | -2188.00% | — | -2152.00% | -7.89% | -28.32 | -1696.85% | 0.00% | 0.00% | 10.60% | -7.47 | -10.85 | — | 89.17 |
| ATOS | Atossa Therapeutics, Inc. | $4.43 | 38.15M | — | — | — | — | -3.65 | 1.30 | — | -0.80 | — | 1.30 | 0.00% | — | — | -31.39% | -1873.25% | -29.54% | 0.00 | — | 14.99 | 14.31 | 2.58 | -1667.00% | — | 45.00% | -22.60% | -4.23 | -1427.53% | 0.00% | 0.00% | 0.00% | -0.80 | -1.05 | — | 7.27 |
| EXOZ | eXoZymes, Inc. | $8.85 | 74.23M | — | — | — | — | -20.08 | 11.29 | — | -19.55 | -10.68 | 11.29 | 0.00% | — | — | -116.80% | -365.14% | -70.65% | 0.13 | — | 8.12 | 7.84 | 1.49 | 18800.00% | — | 50576.00% | -7.56% | -6.38 | -547.95% | 0.00% | 0.00% | 8.39% | -18.43 | -12.28 | — | 25.10 |
| GLSI | Greenwich LifeSciences, I… | $27.72 | 384.05M | — | — | — | — | -9.97 | 62.14 | — | -9.72 | -13.23 | 62.19 | 0.00% | — | — | -341.95% | 1733.85% | -284.78% | 0.00 | — | 2.62 | 2.62 | 0.26 | 7536.00% | — | 1216.00% | -4.61% | -4.66 | 786.86% | 0.00% | 0.00% | 0.00% | -9.58 | -21.11 | — | 25.79 |
| IMMX | Immix Biopharma, Inc. | $8.07 | 270.94M | — | — | — | — | -1.99 | 3.24 | — | -1.17 | — | 3.24 | 0.00% | — | — | -145.76% | 1016.65% | -100.83% | 0.08 | — | 2.33 | 2.26 | 0.74 | -1461.00% | — | 3807.00% | -36.69% | -1.68 | 707.20% | 0.00% | 0.00% | 0.00% | -1.16 | -1.67 | — | -4.58 |
| ONCY | Oncolytics Biotech Inc. | $1.13 | 113.41M | — | — | — | — | -2.33 | 12.32 | — | -1.69 | — | 12.32 | 0.00% | — | — | -189.05% | 442.22% | -107.48% | 0.18 | — | 2.82 | 2.39 | 0.43 | 0.00% | — | -440.00% | -36.90% | -4.03 | 343.91% | 0.00% | 0.00% | 0.00% | -1.68 | -2.16 | — | -35.01 |
| SRZN | Surrozen, Inc. | $27.80 | 238.29M | — | -83% | — | — | -0.55 | -1.64 | 3.28 | -0.37 | -34.54 | -1.64 | 100.00% | -239.69% | -596.56% | -767.91% | 121.02% | -134.46% | -0.40 | — | 5.32 | 5.07 | 1.08 | 159.00% | — | -5669.00% | -50.45% | -2.41 | 83.66% | 0.00% | 0.00% | 0.00% | -0.35 | -0.50 | 0.84 | -8.68 |
| TIL | Instil Bio, Inc. | $8.90 | 60.36M | — | — | — | — | -1.61 | 0.70 | — | -1.48 | — | 0.70 | 0.00% | — | — | -37.51% | -48.30% | -25.16% | 0.51 | -8.18 | 15.76 | 14.35 | -1.25 | -5254.00% | — | -3603.00% | -55.11% | -7.05 | -43.15% | 0.00% | 0.00% | 0.00% | -1.26 | -1.41 | — | -3.11 |
| TLSA | Tiziana Life Sciences Ltd | $1.45 | 86.17M | — | — | — | — | -9.51 | 22.90 | — | -5.21 | — | 22.90 | 0.00% | — | — | -200.16% | -455.01% | -80.79% | 0.03 | -2632.33 | 1.02 | 1.01 | 0.22 | -3529.00% | — | -9006.00% | -1.37% | -0.17 | -50.21% | 0.00% | 0.00% | 2.98% | -5.48 | -70.08 | — | -15.21 |
| TVGN | Tevogen Bio Holdings Inc. | $0.26 | 53.24M | — | — | — | — | -12.18 | -25.05 | — | -12.85 | -0.05 | -25.05 | 0.00% | — | — | 27.16% | 2087.12% | -306.17% | -0.43 | -291.05 | 0.26 | 0.16 | -0.12 | 2330000.00% | — | 4449.00% | -7.18% | -1.33 | 467.53% | 0.00% | 0.00% | 55.48% | -3.15 | -14.07 | — | -89.34 |
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
- CEO
- Cheng Liu
- Employees
- 0
- Beta
- 0.55
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.63) − 1 = — (DCF, example).